Ceftolozane/tazobactam and ceftazidime/avibactam: Two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections

International Journal of Antimicrobial Agents

Volumn 46, Issue 3, 2015, Pages 266-271

  Liscio, Jordan L ^a   Mahoney, Monica V ^b   Hirsch, Elizabeth B ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

cIAI; cUTI; ESBL; KPC; Pseudomonas aeruginosa

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CILASTATIN PLUS IMIPENEM; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PLACEBO; PROBENECID; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CEFTAZIDIME; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; ENZYME INHIBITOR; PENICILLANIC ACID;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEROIDES FRAGILIS; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTERIACEAE; FEVER; GRAM NEGATIVE INFECTION; HEADACHE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION COMPLICATION; INSOMNIA; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PENICILLANIC ACID;

EID: 84940449628     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.05.003     Document Type: Review

References (40)

1. T. Hampton Report reveals scope of US antibiotic resistance threat J Am Med Assoc 310 2013 1661 1663
2. D.M. Sievert, P. Ricks, J.R. Edwards, A. Schneider, J. Patel, A. Srinivasan, and et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 Infect Control Hosp Epidemiol 34 2013 1 14
3. D.L. Paterson, and R.A. Bonomo Extended-spectrum β-lactamases: a clinical update Clin Microbiol Rev 18 2005 657 686
4. K. Bush, and G.A. Jacoby Updated functional classification of β-lactamases Antimicrob Agents Chemother 54 2010 969 976
5. F.J. Pérez-Llarena, and G. Bou β-Lactamase inhibitors: the story so far Curr Med Chem 16 2009 3740 3765
6. K.A. Toussaint, and J.C. Gallagher β-Lactam/β-lactamase inhibitor combinations: from then to now Ann Pharmacother 49 2015 86 98
7. G.A. Jacoby AmpC β-lactamases Clin Microbiol Rev 22 2009 161 182
8. Y. Pfeifer, A. Cullik, and W. Witte Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens Int J Med Microbiol 300 2010 371 379
9. Cubist Pharmaceuticals Zerbaxa™ prescribing information 2015 Cubist Pharmaceuticals Lexington, MA http://www.zerbaxa.com/pdf/PrescribingInformation.pdf [accessed 20.04.15]
10. D.J. Farrell, R.K. Flamm, H.S. Sader, and R.N. Jones Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012) Antimicrob Agents Chemother 57 2013 6305 6310
11. H.S. Sader, D.J. Farrell, M. Castanheira, R.K. Flamm, and R.N. Jones Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12) J Antimicrob Chemother 69 2014 2713 2722
12. H.S. Sader, D.J. Farrell, R.K. Flamm, and R.N. Jones Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012) J Infect 69 2014 266 277
13. D.R. Snydman, L.A. McDermott, and N.V. Jacobus Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates Antimicrob Agents Chemother 58 2014 1218 1223
14. H.S. Sader, P.R. Rhomberg, and R.N. Jones Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains Antimicrob Agents Chemother 58 2014 2434 2437
15. B. Vanscoy, R.E. Mendes, M. Castanheira, J. McCauley, S.M. Bhavnani, A. Forrest, and et al. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model Antimicrob Agents Chemother 57 2013 4134 4138
16. Center for Drug Evaluation and Research, US Food and Drug Administration Zerbaxa (ceftolozane-tazobactam) FDA summary review 2014 FDA http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/206829Orig1s000SumR.pdf [accessed 20.04.15]
17. M. Wooley, B. Miller, G. Krishna, E. Hershberger, and G. Chandorkar Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam Antimicrob Agents Chemother 58 2014 2249 2255
18. G. Chandorkar, A. Xiao, M.S. Mouksassi, E. Hershberger, and G. Krishna Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections J Clin Pharmacol 55 2015 230 239
19. J. Solomkin, E. Hershberger, B. Miller, M. Popejoy, I. Friedland, J. Steenbergen, and et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI) Clin Infect Dis 60 2015 1462 1471
20. F.M. Wagenlehner, O. Umeh, J. Steenbergen, G. Yuan, and R.O. Darouiche Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI) Lancet 385 2015 1949 1956
21. ClinicalTrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). Identifier NCT02070757. https://clinicaltrials.gov/ct2/show/NCT02070757?term=ceftolozane&rank=2 [accessed 15.04.15].
22. ClinicalTrials.gov. Pharmacokinetic and safety study of ceftolozane/tazobactam in pediatric subjects receiving antibiotic therapy for proven or suspected Gram-negative infection or for peri-operative prophylaxis. Identifier NCT02266706. https://clinicaltrials.gov/ct2/show/NCT02266706?term=ceftolozane&rank=4 [accessed 16.04.15].
23. ClinicalTrials.gov. Study to assess the plasma PK & lung penetration of IV ceftolozane/tazobactam in critically ill patients. Identifier NCT02387372. https://clinicaltrials.gov/ct2/show/NCT02387372?term=ceftolozane&rank=1 [accessed 16.04.15].
24. Forest Pharmaceuticals Inc. Avycaz prescribing information. Cincinnati, OH: Forest Pharmaceuticals Inc. http://pi.actavis.com/data
25. R.K. Flamm, D.J. Farrell, H.S. Sader, and R.N. Jones Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012) J Antimicrob Chemother 69 2014 1589 1598
26. H.S. Sader, M. Castanheira, R.E. Mendes, R.K. Flamm, D.J. Farrell, and R.N. Jones Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in US medical centers in 2012 and 2013 Antimicrob Agents Chemother 59 2015 3656 3659
27. H. Chalhoub, M. Tunney, J.S. Elborn, A. Vergison, O. Denis, P. Plesiat, and et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients J Antimicrob Chemother 70 2015 1596 1598
28. J.L. Crandon, V.J. Schuck, M.A. Banevicius, M.E. Beaudoin, W.W. Nichols, M.A. Tanudra, and et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa Antimicrob Agents Chemother 56 2012 6137 6146
29. H.S. Sader, M. Castanheira, R.K. Flamm, D.J. Farrell, and R.N. Jones Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012 Antimicrob Agents Chemother 58 2014 1684 1692
30. D.M. Citron, K.L. Tyrrell, V. Merriam, and E.J. Goldstein In vitro activity of ceftazidime-NXL104 against 396 strains of β-lactamase-producing anaerobes Antimicrob Agents Chemother 55 2011 3616 3620
31. K. Coleman, P. Levasseur, A.M. Girard, M. Borgonovi, C. Miossec, H. Merdjan, and et al. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model Antimicrob Agents Chemother 58 2014 3366 3372
32. M. Castanheira, J.C. Mills, S.E. Costello, R.N. Jones, and H.S. Sader Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase producing strains Antimicrob Agents Chemother 59 2015 3509 3517
33. P. Levasseur, A.M. Girard, C. Miossec, J. Pace, and K. Coleman In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases Antimicrob Agents Chemother 59 2015 1931 1934
34. Center for Drug Evaluation and Research, US Food and Drug Administration Avycaz (ceftazidime-avibactam) FDA summary review 2014 FDA http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM425458.pdf [accessed 20.04.15]
35. H. Merdjan, M. Rangaraju, and A. Tarral Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies Clin Drug Investig 35 2015 307 317
36. C. Lucasti, I. Popescu, M.K. Ramesh, J. Lipka, and C. Sable Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial J Antimicrob Chemother 5 2013 1183 1192
37. J.A. Vazquez, L.D. González Patzán, D. Stricklin, D.D. Duttaroy, Z. Kreidly, J. Lipka, and et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study Curr Med Res Opin 28 2012 1921 1931
38. ClinicalTrials.gov. A study comparing ceftazidime-avibactam versus meropenem in hospitalized adults with nosocomial pneumonia. Identifier NCT01808092. https://clinicaltrials.gov/ct2/show/NCT01808092?term=ceftazidime%2Favibactam&rank=7 [accessed 16.04.15].
39. E.B. Hirsch, and V.H. Tam Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection J Antimicrob Chemother 65 2010 1119 1125
40. P. Nordmann, G. Cuzon, and T. Naas The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria Lancet Infect Dis 9 2009 228 236